MADISON, Wis. – Voximetry, a pioneer in advanced technology to enable personalized treatments for late-stage cancer patients, has appointed Andreas Schulte as General Manager – EMEA/APAC regions. Mr. Schulte has more than 30 years of experience in business and market development in radiation therapy and nuclear medicine. Most recently, Schulte advised various clinical operators in radiation oncology on their market entry into Europe and supported the development of international distributor networks for several start-ups. Andreas has worked as a key advisor and investor for Voximetry since 2020 and now brings his full-time energy and focus to the company, which is poised for global expansion and a CE mark in early 2025.
“Andreas’ fierce advocacy for break-through technologies, wide network of research and clinical leaders, and strong track record of commercial success are the results of his exceptional technical prowess and competitive drive,” said Dr. Sue Wallace, CEO of Voximetry. “Having a seasoned leader in Radiation Oncology business development join our team provides a tangible jump start and strong advantage for the business in new markets.”
Schulte’s career began as a Sales Manager and Product Specialist at HELAX AB, a Swedish manufacturer of therapy planning systems for radiotherapy. After moving to ADAC Laboratories, he successfully launched Pinnacle³ Treatment Planning in multiple European countries and led market consolidation following the acquisition by Philips. Subsequently Schulte managed the expansion of Philips’ Radiation Oncology to international markets in EMEA and APAC.
His analytical thinking, implementation skills, ability to manage complexity with ease, and a powerful can-do attitude have proven effective in introducing innovative technology to rapidly changing markets such as theranostics. Schulte is fluent in three languages and holds a Master of Science in Physics with a major in Theoretical Nuclear Physics from the University of Karlsruhe (KIT). Outside of work, he is a passionate golfer, a connoisseur of international cuisine and a proud husband and father of a brilliant daughter.
ABOUT VOXIMETRY
Voximetry is committed to enabling personalized and effective theranostic treatment options for patients worldwide through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Based in Madison, Wisconsin, Voximetry is a Healthtech software and services company pioneering patient-specific radiopharmaceutical treatment planning (RPT) in advanced stage cancer patients.
ABOUT TORCH
Torch® Dose Assessment software is a proprietary product developed by Voximetry and approved for clinical use by the FDA. Torch design and development continues to be supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R43CA221491 and 2R44CA291564. The product is solely the responsibility of Voximetry and does not represent the official views of the National Institutes of Health.